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Abstract Maximal tumor diameter (MD) is traditionally
an important prognostic factor in breast cancer. It must be
questioned, however, how well a one-dimensional param-
eter alone can represent the actual morphologic condition
of a three-dimensional body. Along with the pathologically
assessed MD and two perpendicular diameters (PDs) of a
lesion, eccentricity (EF) and the three-dimensional
parameters tumor volume (TV) and surface area (TSA)
of 395 ductal invasive breast carcinomas of limited size
(10–40 mm) were calculated. The dependent prognostic
variable was axillary lymph node involvement (ALNI).
MD, TV and TSA area were highly significant predictors of
ALNI; these variables had similar levels of prediction
accuracy (univariate analyses: MD: P = 0.0003, TV:
P = 0.0009, TSA: P \ 0.0001; multivariate analyses:
MD: P = 0.0018, TV: P = 0.0109, TSA: P = 0.0009;
pseudo R-squared values: MD: 0.42, TV: 0.39, TSA: 0.39).
Despite certain variations in tumor shape, TV and
TSA with similar MD, there is no evidence that three-
dimensional pathologic measurements (TV/TSA) are more
precise prognostic predictors of ALNI compared to the
one-dimensional measurement alone.
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Introduction
Tumor size is traditionally one of the most sensitive and
powerful indicators of prognosis in breast cancer, second
only to the presence of nodal metastasis in importance [1].
Thus, it is a critical morphologic feature in staging. How-
ever, the question remains as to how well a one-
dimensional assessment of the largest tumor diameter alone
can represent the actual morphologic condition of a three-
dimensional body. Theoretic models have shown that the
propensity for metastases depends on the total number of
cells of a tumor combined with the probability of each
individual cell to disseminate [2]. This number of cells is
probably better estimated by three-dimensional parameters
such as tumor volume (TV) or surface area (TSA)
(assuming that cells located at the advancing front of the
tumor have a significant probability for dissemination).
Depending on the shape of the tumor, there might be
considerable variability in the TVs and TSAs within
lesions of the same diameter. To exemplify this, a lesion
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measuring 30 9 30 9 30 mm has a TV of 14.14 cm3, a
lesion measuring 30 9 25 9 20 mm one of 7.85 cm3 and a
flat tumor measuring 30 9 22 9 15 mm a volume of only
5.18 cm3; the corresponding TSAs are as follows: 28.27,
19.55, and 15.48 cm2.
Our study addresses two important issues regarding
three-dimensional pathologically measured parameters in
breast cancer:
1. To analyze tumor shape and its variability, and to
assess factors that influence tumor shape
2. To assess the prognostic impact of three-dimensional
size measures: is TV and/or TSA, a more accurate
predictor of axillary lymph node involvement than the
established one-dimensional measurement (maximal
diameter)?
Our study answers the question of whether routine
pathological three-dimensional measurement of a tumor
would have clinical relevance. At this time, the reporting of
these measurements in the current pathology guidelines
and protocols remains optional [3–5]. This study is repor-
ted according to the ‘‘REporting recommendations for
tumor MARKer prognostic studies (REMARK)’’ [6].
Patients and methods
Patient characteristics and data collection (REMARK
requirements 2, 4, 6 [6])
The data of 395 female breast cancer patients whose sur-
gically removed primary carcinomas were pathologically
examined at the Institute for Pathology of the University of
Basel, Switzerland, between 1998 and 2005 form the basis
of the current analysis. We restricted our study to the
analysis of histologically proven unifocal invasive ductal
carcinoma of limited size, in which the largest pathologi-
cally assessed tumor diameters measured between 11 and
40 mm (T1c, T2 B 4 cm). Three-dimensional measure-
ments of each lesion, i.e. three PDs, were available for all
tumors: the maximal diameter (MD) and two PD1, PD2;
the data were organized as follows: MD C PD1 C PD2.
Pathologic lymph node status was known for all patients.
We excluded patients who had multifocal/multicentric
breast tumors or had tumors with clinical or pathological
evidence of any kind of skin or chest wall involvement (T4
category). Patients who had preoperative neoadjuvant
therapy were also excluded. Invasive lobular carcinomas
and rare histologic subtypes with more favorable prognosis
(e.g., tubular carcinoma, papillary carcinoma, medullary
carcinoma) were not considered. In all patients included in
the analysis, hormonal receptor assay, assessment of the
HER-2/neu status and histolopathologic grading according
to the Nottingham modification of the Scarff-Bloom-
Richardson grading scheme had been performed. Further-
more, clinical data concerning age and tumor location
(stratified as inner quadrant, outer quadrant and central
region) were available. The study was carried out in
accordance with the guidelines of the Ethics Committee of
the University of Basel.
Data analysis (REMARK requirements 7–9 [6])
1. Tumor shape (eccentricity). To assess the ‘‘roundness’’
of a tumor, the ‘‘Eccentricity Factor’’ (EF), as previ-
ously described by Schwartz et al. [7], was employed
as a measure of tumor shape. The EF describes the
overall change in tumor shape based on the following
formula (where MD is the maximal diameter and PD2
is the smaller of the two measured PDs:
EF ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1  PD2=MDð Þ2
q
According to this formula, the EF values fall between zero
and one: the higher the EF, the flatter the shape of the tumor.
For example, a lesion measuring 30 9 30 9 30 mm would
have an EF of 0, whereas a lesion measuring 30 9 25 9
20 mm would have an EF of 0.75 (Fig. 1); the highest EF
value in our study population was 0.98 with corresponding
tumor measurements of 29 9 14 9 6 mm.
Fig. 1 Mathematical formula for the eccentricity factor and diagram
illustrating two different eccentricity values. PD2: the smaller of both
PDs; MD: maximal diameter
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2. Tumor volume (TV). For volume computation, the
shape of the tumor was approximated to an ellipsoid.
The volume was computed using the following equa-
tion (where MD is the maximal diameter and PD1/PD2
are diameters that are perpendicular to the MD and to
each other in the three-dimensional space of the tumor
body):
V ¼ 1=6  p  MD  PD1  PD2
3. Tumor surface area. The surface area was
approximated by the following formula (where p =
1.6075):
S ¼ 4p
MD
2
 P PD1
2
 Pþ MD
2
 P PD2
2
 Pþ PD1
2
 P PD2
2
 P
3
 !1=p
4. Dependent variable. The dependent variable of our
study was ALNI, the single most powerful prognostic
factor for primary breast cancer. In our analyses, ALNI
refers not to the nodal status (expressed as either the
presence of negative or positive nodes), but rather the
number of lymph nodes involved.
For every tumor analyzed in this study, we determined
six specific morphologic values: largest diameter (MD),
two PDs (PD1, PD2), TV, TSA and the EF.
Statistical analysis (REMARK requirements 10, 11 [6])
Ordinal linear regression was used to model the relation
between tumor shape (EF) and selected morphologic fea-
tures; to achieve approximately normal distribution for MD/
PD2, this variable was logarithmically transformed, and
regression parameters were expressed as geometric mean
ratios. To evaluate the influence of prognostic factors on
ALNI, particularly MD, TV, TSA and EF, we used univariate
and multivariate Poisson regression method [8]. This model
was performed allowing for overdispersion. TV and TSA
values were logarithmically transformed. Regression
parameters are reported as risk ratios with 95% confidence
intervals. In all tests, a P-value \0.05 was considered sig-
nificant. To decide which of the three multivariate models
including one of the highly confounded variables MD, TV
and TSA has the best impact on ALNI, pseudo R-squared
values according to Cox and Snell were calculated [9]. Sta-
tistical analyses were performed with R Development Core
Team software, version 2.5.0 (Vienna, Austria).
Results (REMARK requirements 12–17 [6])
Clinicopathologic and morphologic characteristics of the
395 patients in the study are summarized in Table 1.
Eccentricity, an expression of tumor shape in invasive
ductal breast carcinoma, is depicted graphically by a box
plot (Fig. 2). The most frequent tumor shape was scalene
ellipsoid, i.e. an ellipsoid in which the lengths of all three
semi-principal axes are different (n = 286, 72.4%). 44
patients (11.1%) had tumors in which the largest diameter
was repeated twice and the third dimension was a smaller
number (oblate spheroid, e.g. 20 9 20 9 15 mm). 56
patients (14.2%) had dimensions in which there was one
larger diameter and the smaller diameter was repeated
twice (prolate spheroid, e.g. 20 9 15 9 15 mm). Only
nine carcinomas (2.3%) had a spherical shape (all three
diameters were identical; EF = 0). 50% of all lesions
ranged between an EF of 0.61 and 0.83. The median
eccentricity value was 0.75. This value means that the ratio
between the MD and the smallest perpendicular diameter
(PD2) is 1:0.67, or that PD2 is approximately 30% less
than the MD. Table 2 shows that established prognostic
factors (histologic grade, estrogen receptor and HER-2/neu
status) had no effect on tumor shape. Only the MD had a
significant influence on the shape of the tumor: the larger
the tumor, the flatter the shape (P \ 0.001).
Using univariate analysis, maximal tumor diameter
(MD), TV and TSA were highly significant predictors of
ALNI; these variables had similar levels of prediction
accuracy (MD: P = 0.0003; TV: P = 0.0009; TSA:
P \ 0.0001; Table 3). Additionally, both perpendicular
tumor diameters had significant association with ALNI
(PD1: P = 0.0086; PD2: P = 0.0106).
Multivariate analyses showed that MD, TV and TSA
remained significant independent predictors of ALNI (MD:
P = 0.0018; TV: P = 0.0109; TSA: P = 0.0009;
Table 4). Since these variables are highly confounded by
the common value MD, they could not be calculated in a
combined model [8]. Therefore, separate calculations were
made for each variable. Table 4 shows the seven-variable
model which includes MD in the calculation (in addition to
MD/TV/TSA we chose to take six co-variables into con-
sideration in the model: age, EF, tumor location, grading,
estrogen receptor and HER-2/neu status). At the bottom of
this table, the TV and TSA values are indicated. The values
of the six co-variables in the calculations including TV and
TSA are quite similar to the calculation including MD,
therefore they were omitted from the table. The pseudo R-
squared values evaluating the three confounded variables
showed the following ranking: MD: 0.42; TV: 0.39; TSA:
0.39.
Discussion (REMARK requirements 19, 20 [6])
In the upcoming era of molecular and genetic character-
ization of breast cancer, the significance of traditional
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anatomic-morphologic prognostic determinants may very
well take a back seat to these new indicators. Efforts
should, however, be made to enhance the accuracy of these
parameters. As before, the size of the tumor remains an
outstanding prognostic factor. Characterization of a three-
dimensional body by a one-dimensional measurement only
seems to be a rather inadequate method.
Studies concerning the three-dimensionality of breast
lesions are mainly a domain of radiologists, where the
tumors assessed are still in vivo [10, 11]. Only few studies
have assessed the three-dimensional extent of surgically
removed carcinomas themselves through pathological
examination of the tumor specimen [12–14]; none of them,
however, have addressed the prognostic significance of
these measurements.
In our study, we analyzed the shape of pathologically
examined breast carcinomas and described its variabilities.
Furthermore, we assessed the prognostic impact of the
three-dimensional size measurement of a lesion, namely
TV and TSA and compared its predictive capacity with the
established one-dimensional measurement, the MD. For
improved uniformity and comparability, we analyzed only
invasive ductal carcinoma, which comprises up to 80–90%
of all invasive breast carcinomas, thereby representing the
single largest group of invasive breast carcinomas. These
carcinomas typically form well-defined solid tumors and
three-dimensional measurement of their size is relatively
precise. Lobular carcinomas were excluded from analysis
because in many cases, there is no grossly well-demarked
mass, and therefore three dimensional assessment of size is
Table 1 Clinicopathologic and morphologic characteristics of the study group
Variable Entire study
group
Tumor size:
11–20 mm
Tumor size:
21–30 mm
Tumor size:
31–40 mm
Total number of cases (%) 395 (100) 167 (41.8) 177 (45.6) 51 (12.6)
Age (yrs)
Mean 61.7 59.8 63.1 63.2
Range 31–88 31–85 31–88 37–86
Tumor diametera, mean (mm)
MD: maximal diameter 22.7 16.3 25.0 36.0
PD1: perpendicular diameter 1 18.8 13.8 20.8 27.9
PD2: perpendicular diameter 2 14.9 11.4 16.5 20.7
Tumor volume (cm3)
Mean 4.2 1.5 4.8 11.4
Range 0.14–25.66 0.14–4.19 0.96–14.14 3.14–25.66
Tumor surface area (cm2)
Mean 12.08 6.20 13.82 25.30
Range 1.46–42.20 1.46–12.57 6.02–28.27 12.98–42.20
Eccentricity factor
Median 0.75 0.70 0.75 0.82
Range 0–0.98 0–0.97 0–0.98 0.25–0.97
Tumor location (%)
Outer quadrants/central region 295 (74.7) 120 (71.9) 135 (76.3) 40 (78.4)
Inner quadrants 100 (25.3) 47 (28.1) 42 (23.7) 11 (21.6)
Grading (%)
G1 52 (13.2) 35 (21.0) 17 (9.6) –
G2 210 (53.2) 88 (52.7) 94 (53.1) 28 (54.9)
G3 133 (33.6) 44 (26.3) 66 (37.3) 23 (45.1)
Estrogen receptor positive (%) 295 (74.7) 130 (77.8) 130 (73.4) 40 (78.4)
HER-2 neu positive (%) 75 (19.0) 24 (14.4) 38 (21.5) 13 (25.5)
Axillary lymph node involvement (%)
Negative 191 (48.4) 93 (55.7) 83 (46.9) 15 (29.4)
1–3 lymph nodes 148 (37.4) 59 (35.3) 68 (38.4) 21 (41.2)
4–10 lymph nodes 38 (9.6) 9 (5.4) 19 (10.7) 10 (19.6)
[10 lymph nodes 18 (4.6) 6 (3.6) 7 (4.0) 5 (9.8)
a The data were organized as follows: MD C PD1 C PD2
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imprecise. More uncommon histologic subtypes were also
excluded because they usually have a more favorable
outcome (e.g., tubular, mucinous, medullary, papillary
carcinomas) compared to invasive ductal and lobular car-
cinomas and the number of cases was so small that they
cannot even be reasonably analyzed as independent
subgroups.
Our data show that most breast carcinomas share a
similar scalene ellipsoid shape and that the variability of
eccentricity is relatively low. Despite certain variations in
tumor shape and at times considerable variabilities in TV
and TSA with similar MD (or within subgroups of diam-
eters with a range of 10 mm, see Table 1), there is no
evidence that the three-dimensional pathologic measure-
ments (TV/TSA) are more precise prognostic predictors of
ALNI compared to MD alone. Of note, even the usually
smaller PDs still have prognostic significance. This implies
that imprecision of pathologic measurement of the largest
dimension of the tumor might not be so critical.
Even in subgroups with tumors at extremes of shape
(namely spherical or excessively flattened), three-dimen-
sional measurement is not a more powerful predictor than
MD. We expected this to be the case with flattened tumors,
which have correspondingly lower TV and TSA. A possi-
ble explanation could have been that these tumors had
more often characteristics that are associated with tumor
aggressiveness (e.g., poor grading, hormonal receptor
negative and HER-2 neu positive status). However, this
was not the case; only MD had a significant influence on
the shape of the tumor. The fact that tumors become flatter
with increasing size probably has to do with their blood
supply. Wapnir et al. demonstrated an inverse relationship
between microvessel counts and TV [13].
The finding that three-dimensional measurements are
not more powerful predictors of prognosis than tumor size
alone might rather support the notion that only a small
subpopulation of tumor cells in a whole tumor population
has metastatic potential, and that this might not be
dependent on total TV or total amount of tumor cells, but
possibly on the individual quantity of metastases initiating
Fig. 2 Box plot for eccentricity of invasive ductal breast carcinoma.
The box plot shows the median value (closed circle) and the 25% and
75% percentiles. The dashed lines label the 10% and 90% percentile,
while the open circles represent outlying values
Table 2 Associations between clinicopathologic/morphologic char-
acteristics and tumor shape (eccentricity), univariate analysis
Variable GMR (95% CI) P-value
Maximal tumor diameter 1.05 (1.03–1.06) \0.001
Poor histologic grading (G3) 0.98 (0.91–1.06) 0.640
ER-negative status 1.02 (0.96–1.08) 0.617
c-erbB2 positive status 1.01 (0.95–1.08) 0.703
GMR: Geometric Mean Ratio; CI: Confidence Interval
Table 3 Associations between
clinicopathologic/morphologic
characteristics and axillary
lymph node involvement:
univariate analysis
OR: Odds Ratio; CI: Confidence
Interval
a The data were organized as
follows: MD C PD1 C PD2
Variable OR (95% CI) P-value
Age 1.02 (0.88–1.19) 0.788
Tumor diametera
MD: maximal diameter 1.28 (1.12–1.45) 0.0003
PD1: perpendicular diameter 1 1.22 (1.05–1.41) 0.0086
PD2: perpendicular diameter 2 1.26 (1.05–1.49) 0.0106
Tumor volume 1.46 (1.17–1.82) 0.0009
Tumor surface area 1.79 (1.28–2.50) \0.0001
Eccentricity factor 0.94 (0.33–3.02) 0.920
Tumor localization: outer quadrants/ central region 1.43 (0.87–2.47) 0.177
Poor histologic grading (G3) 2.73 (1.26–7.47) 0.0249
ER-negative status 1.59 (1.05–2.37) 0.0240
HER-2 neu positive status 2.04 (1.34–3.04) \0.0001
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tumor stem cells or the gain of metastatic possibility of
these cells over time [15]. Furthermore, there is a mathe-
matical explanation for the statistical lack of higher impact
of three-dimensionality: the multiplication of three metric
variables results in more variability of the predictor, and
this leads to higher variability of the data and to blurred
statistical trends.
According to the current pathology guidelines and pro-
tocols, a three-dimensional measurement of breast
carcinomas remains optional [3–5], with the comment in
the College of American Pathologists protocol that this has
not yet been validated [4]. Our data do not support the
assumption that three-dimensional measurement has an
improved prognostic capability in comparison with tradi-
tional one-dimensional measurement. Nevertheless, three-
dimensional pathologic measurement of a tumor provides
useful information. It allows a more exact morphologic
description of the lesion compared to the assessment of
MD alone. Furthermore, a routinely performed three-
dimensional measurement helps the pathologist in identi-
fying the plane of the longest tumor axis and to assess the
truly largest dimension.
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